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Summary. Gene therapy is the use of nucleic acids as 
drugs. Thus, ways had to be developed to deliver this 
new generation of drugs to target tissues. Various viral 
and non-viral vectors have been engineered to carry 
potentially therapeutic nucleic acids into diseased organs 
or target cells. The brain offers a particular challenge for 
gene delivery to its constituent cells: it is encased by the 
skull, separated from the general circulation by the blood 
brain barrier, and made up of mostly non-dividing cells. 
The skull limits direct injection of vectors into the brain, 
the blood brain barrier inhibits the easy entry of vectors 
injected into the bloodstream, and post mitotic target 
cells restrict what type of vector can be used to deliver 
genes to the brain. We will discuss the main challenges 
faced by gene delivery to the brain, i.e. immune 
responses to the delivery vectors and therapeutic 
transgenes and length of duration of the therapy 
specifically as applied to Parkinson's disease. We will 
also discuss therapeutic strategies, which could be 
implemented to treat Parkinson's disease, and the models 
in which they have been tested. 
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Introduction 
Parkinson's disease (PD) is a late-onset 
neurodegenerative disorder. It is characterised by the 
triad of bradykinesia, rigidity and resting tremor. 
Postural instability and asymmetry of motor signs in the 
limbs are also important features. 
To make an accurate diagnosis of PD, different 
Parkinson-like syndromes, which may be due to drugs, 
cerebrovascular disease or other neurodegenerative 
causes need to be excluded. The gradual onset of the 
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disease and patients presenting a wide range of 
symptoms including pain, cognitive changes and 
depression, as well as symptoms complicated by the 
long term effects of drug treatment make diagnosis 
difficult and in over 20% of cases inaccurate (Hughes et 
al., 1992).  The  prevalence of PD in the general 
population is approximately 0.3% and rises dramatically 
over the age of 65 with almost 3% of people affected 
above that age. Mortality in PD is two to fivefold- 
increased (Berger et al., 2000). 
Primarily, the pathology is due to progressive 
selective degeneration of dopaminergic neurones in the 
substantia nigra pars compacta. The presence of Lewy 
bodies, i.e., fibrillar neuronal inclusions, containing 
ubiquitin and a-synuclein, are the histological hallmark 
of the disease (Irizarry et al., 1998). Lewy bodies 
reported in individuals without clinical features of PD 
suggest a presymptomatic phase of the disease, which 
probably lasts 4 to 5 years as documented in a 
longitudinal positron emission tomography imaging 
study (Morrish et al., 1996). As a consequence of the 
degeneration of dopaminergic nigrostriatal fibres, striatal 
dopamine levels are reduced and the finely tuned 
circuitry of excitatory and inhibitory impulses in the 
basal ganglia is disturbed. Resulting subthalamic 
overactivity is considered to play a key role in the 
pathophysiology of PD (Blandini et al., 2000). 
Current hypotheses include oxidative stress,  
mitochondrial dysfunction, immune mechanisms and 
excitotoxicity as possible mechanisms of nigro-striatal 
degeneration. Environmental factors also seem to 
contribute to the disease process and recently 
administration of a natural occurring pesticide, 
Rotenone, has been shown to reproduce the behavioural, 
anatomical, neurochemical and neuropathological 
features of PD in rats (Betarbet et al., 2000). A minority 
of mostly atypical cases is familial and several 
responsible mutations have been identified (Hattori et 
al., 2000). 
To date therapeutic strategies are mainly 
symptomatic. Dopamine replacement with its precursor 
levodopa in combination with a decarboxylase inhibitor 
continues to be the most effective treatment decreasing 













